EGFR and non-small cell lung carcinoma: Similarly, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1) is a synthetic small molecule that has been reported as an ATP-competitive selective inhibitor of IKK2 [80], and subsequent discoveries presented TPCA-1 as a direct dual inhibitor of STAT3 and NF-κB that effectively regresses mutant EGFR-associated human NSCLC [77].